Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc (NYSE: MRK) has entered into a procurement agreement with the U.S. government for molnupiravir (MK-4482), an antiviral candidate for mild to moderate COVID-19. Molnupiravir is currently being evaluated in Phase 3 MOVe-OUT study to treat non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes.

Merck Inks Molnupiravir Supply Pact With US Government For COVID-19

Shares of Merck & Co. Inc. rose 0.9% in premarket trading Wednesday, after the drug maker announced a supply agreement with the U.S. government for molnupiravir, its investigational oral antiviral candidate to treat mild to moderate COVID-19. Molnupiravir is currently undergoing a Phase 3 clinical trial for treating COVID-19 in non-hospitalized patients with at least one risk factor.

Merck enters $1.2 billion agreement to supply U.S. government with potential COVID-19 treatment

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Supply Agreement with U.S. Government for Molnupiravir

Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19

Merck & Co., Inc. (MRK) Management Presents at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Conference (Transcript)

Merck & Co., Inc. (MRK) CEO Ken Frazier Presents at CECP 2021 CEO Investor Forum (Transcript)

MADISON, N.J.--(BUSINESS WIRE)--MSD Animal Health to Acquire Assets of LIC Automation Ltd.

MSD Animal Health to Acquire Assets of LIC Automation Ltd.

Merck & Co Inc (NYSE: MRK) has announced new data from Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Keytruda (pembrolizumab) plus Lenvima from Eisai Co Ltd (OTC: ESALY), and Lenvima plus everolimus versus Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) in renal cell carcinoma (RCC). Results from a new analysis evaluating health-related quality of life (HRQoL) based on patient-reported outcomes are being presented during an oral abstract session.

Merck/Eisai's Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to Sunitinib

KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New Data on KEYTRUDA® Plus LENVIMA® Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting

Chewy

Regeneron Pharmaceuticals

Blackrock Inc

Campbell Soup

Companies reporting earnings or speaking with investors this week include Chewy, Campbell Soup, Merck, UPS, and Regeneron. Plus, inflation data and sentiment surveys.

Chewy, Regeneron, UPS, Merck, and Other Stocks to Watch This Week

AstraZeneca

AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating Lynparza (olaparib) in a subset of early breast cancer patients. Results will be presented at the 2021 American Society of Clinical Oncology Annual Meeting and published in the New England Journal of Medicine.

AstraZeneca, Merck Lynparza Earns Win in Early Breast Cancer, Showing Potential in Post-Surgery Setting

Merck & Co (NYSE: MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment in a subset of patients with renal cell carcinoma (RCC). The trial included RCC patients at intermediate-high or high risk of recurrence following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions.

Merck's Keytruda Shows Clinical Benefit in Post-Surgery Kidney Cancer Setting

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Given After Surgery Reduced Risk of Disease Recurrence or Death 32% vs Placebo as Adj Therapy in Patients with Renal Cell Carcinoma

Merck's KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA Reduced Risk of Invasive Disease Recurrence or Death 42% vs Placebo in Adj Treatment of BRCA Mutated HER2-Neg Early Breast Cancer

LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial

In a move to free up a cash windfall and streamline the business, Merck & Co Inc (NYSE: MRK) had long planned to slice away its women's health business into a standalone spinoff. As of Thursday, that spinoff, dubbed Organon, is now a public entity all its own.

Merck Completes Women's Health Organon Spinoff

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #merck--Merck Announces Completion of Organon & Co. Spinoff

Merck Announces Completion of Organon & Co. Spinoff

The Merck spinoff Organon will likely do quite well. OGN stock is likely to be worth $52.77, or 48% above the when-issued price right now.

Merck Spinoff Organon Will Do Well Over Time

Freeport-McMoRan

Fidelity MSCI Consumer Staples ETF

iShares Russell 1000 Value ETF

Procter & Gamble

Vanguard Dividend Appreciation ETF

With solid fundamental metrics, these defensive stocks deserve your attention now The post 7 Best Stocks To Buy To Hedge Against A Potential Downturn appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn't matter if you have $500 in savings or $5 million.

7 Best Stocks To Buy To Hedge Against A Potential Downturn

Sutro Biopharma Inc

Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA Germany (OTC: MKGAF). The payment is related to a patient enrollment achievement in the Phase 1 dose-escalation and expansion study of M1231 in adult patients with metastatic solid tumors.

Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck

KENILWORTH, N.J. & BRIDGEWATER, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Sanofi's First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States

Merck and Sanofi's First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?

Why Merck (MRK) is a Great Dividend Stock Right Now

Automatic Data Processing

Ecolab

Home Depot

Coca-Cola

PepsiCo

This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: June 1-14, 2021

"The Dow adds a stock if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration." Dow stocks represent nine of eleven sectors. Dow tracks utilities as a separate index and omits real estate. Broker top ten target-estimated net-gains ranged 8.1%-22.1% topped by MRK 5/27/21.

June Dogs Of The Dow: Merck Tops By Net Gains

Lannett Company

Organon & Co

S&P Global

NEW YORK, May 27, 2021 /PRNewswire/ -- Organon & Co. (NYSE: OGN) will be added to the S&P 500 prior to the open of trading on Thursday, June 3, replacing HollyFrontier, which will be removed from the S&P 500 effective prior to the open of trading on Friday, June 4. HollyFrontier will replace Service Properties Trust (NASD:SVC) in the S&P MidCap 400, and Service Properties Trust will replace Lannett Co Inc. (NYSE:LCI) in the S&P SmallCap 600 also effective prior to the open on June 4.

Organon Set to Join S&P 500; HollyFrontier to Join S&P MidCap 400; Service Properties Trust to Join S&P SmallCap 600

AbbVie

Bristol-Myers

General Motors

Sirius XM Holdings Inc

Warren Buffett is a legendary investor, but he's wrong to pare down these top-tier stocks.

News for Merck Stock (MRK)